Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Above 200 Day Moving Average – Here’s Why

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.34 and traded as high as $14.95. Enanta Pharmaceuticals shares last traded at $14.73, with a volume of 254,941 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ENTA shares. JPMorgan Chase & Co. began coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price target on the stock. Jefferies Financial Group raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $14.00 to $20.00 in a research note on Wednesday, October 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Evercore ISI dropped their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Monday, September 15th. Finally, Westpark Capital lifted their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.33.

Enanta Pharmaceuticals Trading Up 4.2%

The company has a market capitalization of $425.11 million, a PE ratio of -3.85 and a beta of 0.96. The business’s fifty day moving average is $12.16 and its two-hundred day moving average is $9.34.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.26. The business had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. As a group, equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, insider Yat Sun Or sold 2,390 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $34,009.70. Following the completion of the sale, the insider directly owned 371,392 shares of the company’s stock, valued at approximately $5,284,908.16. This represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jay R. Luly sold 4,743 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the sale, the chief executive officer owned 858,026 shares of the company’s stock, valued at $12,209,709.98. This trade represents a 0.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 11,961 shares of company stock worth $170,149 in the last ninety days. Insiders own 13.89% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio lifted its stake in Enanta Pharmaceuticals by 8.3% in the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Enanta Pharmaceuticals by 8.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock worth $216,000 after buying an additional 1,383 shares in the last quarter. AlphaQuest LLC grew its holdings in Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 1,562 shares in the last quarter. Sio Capital Management LLC increased its holdings in Enanta Pharmaceuticals by 1.0% during the second quarter. Sio Capital Management LLC now owns 178,774 shares of the biotechnology company’s stock valued at $1,352,000 after buying an additional 1,770 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Enanta Pharmaceuticals by 13.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock valued at $197,000 after acquiring an additional 1,940 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.